Company Overview and News

Sir Ron Brierley still walks the takeover path

Proving he can walk and chew gum at the same time, Sir Ron Brierley's current plaything Mercantile Investment has two takeover bids on the go as it continues to try to suck up market minnows.

Sir Ron Brierley still walks the takeover path

Proving he can walk and chew gum at the same time, Sir Ron Brierley's current plaything Mercantile Investment has two takeover bids on the go as it continues to try to suck up market minnows.

VCS partners with Stone Resources

Contractors Doug Grewar and John Silverthorne are planning to develop the Brightstar gold project near Laverton, after their private company signed an agreement with project owner Stone Resources Australia.

MHM Metals Ltd pending details on acquisition

MHM Metals Ltd (ASX:MHM) has been granted a trading halt by the ASX, pending details in relation to a Non-Binding Proposal made to KIN Mining NL (ASX:KIN). The company advised that it has acquired voting power to approximately 10% of the issued share capital of KIN Mining NL. This investment in KIN is part of MHM’s strategy to create new business opportunities in the resources sector. The halt will remain in place until the opening of trade on Thursday 14th July 2016, or earlier if an announcement is made to the market.

Settlement of Legal Claim




Cancellation of Shares


MHM Metals Ltd to reveal Brightstar Gold project intentions

Cashed-up MHM Metals Ltd (ASX:MHM) will reveal its intentions regarding the Brightstar Gold Project located in the Laverton region of Western Australia when it moves out of a trading halt. In January 2016, MHM signed an agreement with owner Stone Resources (ASX:SHK) to acquire a 50% interest in the Brightstar gold project boasting a JORC gold resource and a gold treatment plant. This was conditional upon MHM completing due diligence to its satisfaction and obtaining all necessary shareholder and regulatory approvals.

Trading Halt


Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...